<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745625</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-102</org_study_id>
    <nct_id>NCT03745625</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Double-crossover, Propofol-controlled, Two-stage Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of IV Maintenance Dose After An Initial Dose and IV Single Loade Dose Plus Maintenance Dose of HSK3486 Emulsion fo Injection in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-center, open-label, randomized,two-way crossover,
      propofol-controlled, two-stage study evaluating the safety and
      pharmacokinetics/pharmacodynamics of IV maintenance dose after an initial dose and IV single
      loade dose plus maintenance dose of HSK3486 emulsion for injection in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure（systolic, diastolic and mean arterial pressure）</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood oxygen saturation</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>from the baseline to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation Sedation Scale( scores：+4~-5)</measure>
    <time_frame>-30 minutes before administration until the subject is completely awakened post administration on day 1</time_frame>
    <description>Change from baseline in Richmond Agitation Sedation Scale(RASS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index</measure>
    <time_frame>-30 minutes before administration until the subject is completely awakened post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation/anesthesia satisfaction, satisfaction assessment of subjects, anesthesiologists, and endoscopic physicians</measure>
    <time_frame>-30 minutes before administration until the subject is completely awakened post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma concentration at the end of infusion</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>area under curve from time 0 to the last measurable blood sampling time (AUC0-last)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>area under curve from time 0 to infinite time (AUC0-inf)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak concentration</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>time to peak observed (Tmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Anesthesia</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.
Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.
Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females with full capacity for civil conduct, aged ≥ 18 and ≤ 49
             years old;

          2. Body weight &gt; 45 kg, and body mass index (BMI) ≥ 19 and ≤26 kg/m2;

          3. Blood pressure between 90-140/60-90 mmHg; heart rate between 60-99 bpm; body
             temperature between 35.8-37.5 °C; respiration rate between 12-20 breaths per minute;
             SpO2 when inhaling &gt; 95%;

          4. Normal physical examinations, laboratory examinations (routine blood test, blood
             biochemistry and routine urinalysis), and 12-Lead ECG, or abnormal but without
             clinical significance; no potential difficult airway (modified Mallampati score
             I-III);

          5. No previous history of major organ primary diseases, such as liver, kidneys, digestive
             tract, blood, and metabolic diseases; no history of malignant hyperthermia and other
             genetic conditions; no history of mental/neurological diseases; No history of
             epilepsy; no contraindications for deep sedation/general anesthesia; no clinically
             significant history of anesthesia accidents;

          6. Subjects must understand the procedures and methods of this study, and be willing to
             provide informed consent and to complete the trial in strict accordance with trial
             protocol.

        Exclusion Criteria:

          1. Known sensitivity to propofol, excipients in propofol medium-/long-chain triglyceride
             emulsion injection, excipients in HSK3486 emulsion injection (soybean oil, glycerin,
             triglyceride, egg lecithin, sodium oleate, and sodium hydroxide); history of drug
             allergies (including anesthetics), allergic diseases, or those with hyperactive immune
             response;

          2. History of drug abuse or any signs of chronic benzodiazepines use (such as insomnia,
             anxiety, spasms) within 3 months prior to screening, or a positive urine drug test
             during screening;

          3. Participated in clinical trials involving any medications or medical devices within 3
             months prior to screening, or subjects who have participated in 3 or more drug
             clinical trials within the past year;

          4. Serious infection, trauma or major surgery within 4 weeks before screening; or acute
             disease with clinical significance (determined by the investigator) within 2 weeks
             before screening, including GI diseases or infections (such as respiratory or CNS
             infections);

          5. In receipt of propofol, other sedatives/anesthetics and/or opioid analgesics or
             compounds containing analgesics within 3 days prior to screening;

          6. In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or
             food supplements (such as vitamins and calcium supplements) other than contraceptives,
             paracetamol, oral non-steroidal anti-inflammatory drugs, topical over-the-counter
             preparations, within 2 weeks prior to enrollment; unless the principal investigator
             (PI) and the sponsor agree that the medication has no effect on the safety and PK/PD
             results of the trial;

          7. History of cardiovascular diseases such as: postural hypotension, severe arrhythmia,
             heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6
             months before screening, tachycardia/bradycardia requiring medication, third-degree
             atrioventricular block or QTcF interval ≥ 450 ms (Fridericia's correction formula);

          8. Impaired respiratory function, history of obstructive pulmonary disease, history of
             asthma, sleep apnea syndromes; history of failed tracheal intubation; history of
             bronchospasm requiring treatment within 3 months prior to screening; acute upper
             respiratory tract infection, and with obvious symptoms such as fever, wheezing, nasal
             congestion and cough within 1 week prior to baseline;

          9. History of GI tract diseases: Gastrointestinal obstruction, active GI bleed, potential
             for reflux and aspiration;

         10. Laboratory results that meet any of the following during screening/enrollment:

               -  Positive test for either HBsAg, HCV, HIV, or syphilis;

               -  Abnormal hepatic or renal function confirmed after re-examination;

                    -  ALT or AST &gt; 1×ULN;

                    -  Creatinine &gt; 1×ULN;

                    -  TBIL &gt; 1.5×ULN;

         11. History of alcohol abuse within 3 months prior to screening, abuse defined as average
             of &gt; 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol
             or 150 mL wine), or positive blood alcohol concentration during screening;

         12. Blood donation or blood loss ≥ 200 mL within 30 days before the trial; plasma donation
             or plasma exchange within 7 days before the trial;

         13. Subjects who continue to smoke, drink alcohol, or consume any food or beverages
             containing xanthine or caffeine, to participate in strenuous physical activities and
             other factors that may affect drug absorption, distribution, metabolism, and excretion
             within 2 days prior to enrollment; subjects who are unable to fast for 6 hours prior
             to dose administration;

         14. Subjects expected to have surgery or hospitalization during the trial;

         15. Women who are pregnant or breastfeeding; women of child-bearing potential or men who
             are unwilling to use contraception during the trial; subjects who are planning
             pregnancy within 1 month after the completion of the trial (including male subjects);

         16. Subjects judged by the investigator to be unsuitable for participating in this trial
             for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

